Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lutetium Lu 177-DOTA-IPN01087

A radioconjugate consisting of the neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227), that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-IPN01087 binds to NTR1 expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to NTR1-expressing cells. NTR1, a G-protein coupled receptor, is highly expressed in ductal pancreatic adenocarcinoma but not in normal pancreatic tissue.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:177Lu-3BP-227
177Lu-DOTA-3BP-227
177Lu-DOTA-IPN01087
177Lu-IPN01087
lutetium Lu 177 DOTA-3BP-227
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search